BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wei L, Han T, Yang D, Heo J, Shang J, Cheng J, Chen X, Xie Q, Kim JH, Kalmeijer R, Ouwerkerk-Mahadevan S, Hoeben E, Lenz O, Verbinnen T, Sinha R, Li M, Scott J, Peeters M, Witek J; TIGER team. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea. J Gastroenterol Hepatol 2016;31:912-20. [PMID: 26777137 DOI: 10.1111/jgh.13288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Bourgeois S, Horsmans Y, Nevens F, van Vlierberghe H, Moreno C, Beumont M, Vijgen L, van Eygen V, Luo D, Hillewaert V, Van Remoortere P, van de Logt J, Ouwerkerk-Mahadevan S. Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen. Antimicrob Agents Chemother 2017;61:e01217-17. [PMID: 28971875 DOI: 10.1128/AAC.01217-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Snoeys J, Beumont M, Monshouwer M, Ouwerkerk-Mahadevan S. Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling. Clin Pharmacokinet 2017;56:781-92. [PMID: 27896690 DOI: 10.1007/s40262-016-0476-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ren S, Jin Y, Huang Y, Ma L, Liu Y, Meng C, Guan S, Xie L, Chen X. HCV NS3Ag: a reliable and clinically useful predictor of antiviral outcomes in genotype 1b hepatitis C virus-infected patients. Eur J Clin Microbiol Infect Dis 2016;35:1195-203. [PMID: 27173787 DOI: 10.1007/s10096-016-2653-5] [Reference Citation Analysis]
4 Borba HH, Wiens A, Steimbach LM, Perlin CM, Tonin FS, Pedroso ML, Fernandez-Llimos F, Pontarolo R. Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. Eur J Clin Pharmacol 2017;73:1-14. [PMID: 27757504 DOI: 10.1007/s00228-016-2146-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
5 Raja R, Baral S, Dixit NM. Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. Immunol Rev 2018;285:55-71. [PMID: 30129199 DOI: 10.1111/imr.12689] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
6 Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
7 Grad R, Thombs BD, Tonelli M, Bacchus M, Birtwhistle R, Klarenbach S, Singh H, Dorais V, Holmes NM, Martin WK. Recommendations on hepatitis C screening for adults. CMAJ. 2017;189:E594-E604. [PMID: 28438952 DOI: 10.1503/cmaj.161521] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
8 Wei L, Shang J, Ma Y, Xu X, Huang Y, Guan Y, Duan Z, Zhang W, Gao Z, Zhang M, Li J, Jia J, Yang Y, Wen X, Wang M, Jia Z, Ning B, Chen Y, Qi Y, Du J, Jiang J, Tong L, Xie Y, Wu JJ. Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C. J Clin Transl Hepatol 2019;7:221-5. [PMID: 31608213 DOI: 10.14218/JCTH.2019.00018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]